Real-world use of ivacaftor in Canada: A retrospective analysis using the Canadian Cystic Fibrosis Registry
- 30 March 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (6), 1040-1045
- https://doi.org/10.1016/j.jcf.2021.03.008
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equationsEuropean Respiratory Journal, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- Effects of Gender and Age at Diagnosis on Disease Progression in Long-term Survivors of Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centreThorax, 2002
- Trends in Pulmonary Function in Patients with Cystic Fibrosis Correlate with the Degree of Glucose Intolerance at BaselineAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: A consensus conference reportDiabetes Research and Clinical Practice, 1999
- Severity of cystic fibrosis in patients homozygous and heterozygous for ΔF508 mutationThe Lancet, 1991
- The Relation between Genotype and Phenotype in Cystic Fibrosis — Analysis of the Most Common Mutation (ΔF508)The New England Journal of Medicine, 1990
- Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosisThe Lancet, 1990